ES2085966T3 - Mecanismos geneticos de supresion de tumores. - Google Patents

Mecanismos geneticos de supresion de tumores.

Info

Publication number
ES2085966T3
ES2085966T3 ES91307791T ES91307791T ES2085966T3 ES 2085966 T3 ES2085966 T3 ES 2085966T3 ES 91307791 T ES91307791 T ES 91307791T ES 91307791 T ES91307791 T ES 91307791T ES 2085966 T3 ES2085966 T3 ES 2085966T3
Authority
ES
Spain
Prior art keywords
suppression
tumors
genetic mechanisms
genetic
mechanisms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91307791T
Other languages
English (en)
Inventor
Wen-Hwa Lee
Phang-Lang Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24291866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2085966(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of California filed Critical University of California
Application granted granted Critical
Publication of ES2085966T3 publication Critical patent/ES2085966T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

UN METODO PARA UTILIZAR PRODUCTOS GENETICOS P53 CDNA Y P53 PARA LA SUPRESION DEL FENOTIPO NEOPLASTICO.
ES91307791T 1990-08-24 1991-08-23 Mecanismos geneticos de supresion de tumores. Expired - Lifetime ES2085966T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57340590A 1990-08-24 1990-08-24

Publications (1)

Publication Number Publication Date
ES2085966T3 true ES2085966T3 (es) 1996-06-16

Family

ID=24291866

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91307791T Expired - Lifetime ES2085966T3 (es) 1990-08-24 1991-08-23 Mecanismos geneticos de supresion de tumores.

Country Status (11)

Country Link
EP (2) EP0710722A1 (es)
JP (1) JP2838090B2 (es)
KR (1) KR970000189B1 (es)
AT (1) ATE136793T1 (es)
AU (3) AU653356B2 (es)
CA (1) CA2047090C (es)
DE (1) DE69118789T2 (es)
DK (1) DK0475623T3 (es)
ES (1) ES2085966T3 (es)
FI (1) FI105014B (es)
NO (1) NO312681B1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE911115A1 (en) * 1990-04-10 1991-10-23 Canji Inc Gene therapy for cell proliferative diseases
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
EP0575518A1 (en) * 1991-03-06 1993-12-29 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
DK0643726T3 (da) * 1992-05-26 2000-03-20 Seed Capital Investments Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei
WO1994006910A1 (en) * 1992-09-18 1994-03-31 Canji, Inc. Gene therapy by retroviral vector with tumor suppressive gene
GB9224784D0 (en) * 1992-11-26 1993-01-13 Univ Dundee Cellular protein
CA2086577A1 (en) * 1992-12-31 1994-07-01 Rick E. Preddie Potential target for immunotherapy to prevent replication of hiv (aids virus) in humans: cdna and protein for a putative regulator of hiv gag polyprotein expression reconstructed from the antisense strand of human p53 gene
US6160106A (en) * 1993-10-12 2000-12-12 Yeda Research & Development Co., Ltd. Tumor suppressor genes, proteins encoded thereby and use of said genes and proteins
IL107250A (en) * 1993-10-12 2001-08-08 Yeda Res & Dev Dna molecules involved in programmed cell death, proteins encoded thereby and methods and compositions using said dna molecules and proteins
AU7983294A (en) * 1993-10-19 1995-05-08 Regents Of The University Of Michigan, The P53-mediated apoptosis
FR2712602B1 (fr) * 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
US5700657A (en) * 1993-12-13 1997-12-23 Genzyme Corporation Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby
US5721340A (en) * 1994-11-28 1998-02-24 The Wistar Institute Of Anatomy & Biology p53 proteins with altered tetramerization domains
US5573925A (en) * 1994-11-28 1996-11-12 The Wistar Institute Of Anatomy And Biology P53 proteins with altered tetramerization domains
JPH11510386A (ja) 1995-07-28 1999-09-14 マリー キュリー キャンサー ケア 輸送蛋白質およびそれらの使用
GB9519299D0 (en) 1995-09-21 1995-11-22 Farrar Gwyneth J Genetic strategy
GB9519275D0 (en) 1995-09-21 1995-11-22 Univ Dundee Substances and their therapeutic use
US5847083A (en) * 1996-08-21 1998-12-08 The Wistar Institute Of Anatomy And Biology Modified p53 constructs which enhance DNA binding
US6656480B2 (en) 1996-01-11 2003-12-02 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
US6828431B1 (en) 1999-04-09 2004-12-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6861506B1 (en) 1996-01-11 2005-03-01 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
US7241876B2 (en) 1996-01-11 2007-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US8551970B2 (en) 1996-04-02 2013-10-08 Optigen Patents Limited Genetic suppression and replacement
GB9606961D0 (en) 1996-04-02 1996-06-05 Farrar Gwyneth J Genetic strategy III
US5876972A (en) * 1996-09-23 1999-03-02 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Nucleic acid molecules coding for tumor suppressor proteins and methods for their isolation
US6194191B1 (en) 1996-11-20 2001-02-27 Introgen Therapeutics, Inc. Method for the production and purification of adenoviral vectors
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
CA2214461A1 (en) 1997-09-02 1999-03-02 Mcgill University Screening method for determining individuals at risk of developing diseases associated with different polymorphic forms of wildtype p53
WO1999050287A2 (en) * 1998-03-27 1999-10-07 The Johns Hopkins University P40 protein acts as an oncogene
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
WO2006021803A2 (en) 2004-08-27 2006-03-02 Cyclacel Limited Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases
CN101080488A (zh) 2004-11-03 2007-11-28 因特罗根治疗公司 生产和纯化腺病毒载体的新方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362623A (en) * 1991-06-14 1994-11-08 The John Hopkins University Sequence specific DNA binding by p53
IE911115A1 (en) * 1990-04-10 1991-10-23 Canji Inc Gene therapy for cell proliferative diseases
CA2064555A1 (en) * 1990-06-27 1991-12-28 Arnold J. Levine Probes for detecting mutant p53

Also Published As

Publication number Publication date
KR970000189B1 (en) 1997-01-06
FI913978A (fi) 1992-02-25
AU8262991A (en) 1992-02-27
CA2047090A1 (en) 1992-02-25
FI913978A0 (fi) 1991-08-23
EP0475623A1 (en) 1992-03-18
JP2838090B2 (ja) 1998-12-16
NO912665D0 (no) 1991-07-08
JPH0759579A (ja) 1995-03-07
EP0710722A1 (en) 1996-05-08
ATE136793T1 (de) 1996-05-15
AU653356B2 (en) 1994-09-29
DE69118789T2 (de) 1996-09-26
EP0475623B1 (en) 1996-04-17
DE69118789D1 (de) 1996-05-23
CA2047090C (en) 1998-08-04
NO312681B1 (no) 2002-06-17
DK0475623T3 (da) 1996-05-13
AU4765197A (en) 1998-03-26
AU8183694A (en) 1995-02-23
FI105014B (fi) 2000-05-31
NO912665L (no) 1992-02-25

Similar Documents

Publication Publication Date Title
ES2085966T3 (es) Mecanismos geneticos de supresion de tumores.
FI905535A0 (fi) Foerfarande foer reproduktion av barrtraed genom somatisk embryogenes.
EP0449597A3 (en) Highly directional optical system and optical sectional image forming apparatus employing the same
EP0587067A3 (en) Electrophotographic device.
FR2711255B1 (fr) Appareillage de formation d'image.
EP0638839A3 (en) Apparatus for processing photosensitive material.
FI913695A0 (fi) Anordning och foerfarande foer identifiering av bildomraode.
EP0661785A3 (en) Laser device.
EP0614124A3 (en) Exposure device.
EP0629915A3 (en) Device for arranging light-sensitive material.
EP0578528A3 (en) Photosensitive electrophotographic element, and electrophotographic apparatus using the same.
EP0581519A3 (en) Optical playback device.
EP0594132A3 (en) Recording apparatus for an optical recording medium.
EP0566146A3 (en) Optical disk device.
DE68920881D1 (de) Bildreproduktionsverfahren.
EP0649071A3 (en) Processor.
EP0644046A3 (en) Printing plate maker with laser.
EP0643324A3 (en) Photographic processing device.
EP0627656A3 (de) Fotografisches Aufzeichnungsmaterial.
EP0631186A3 (en) Apparatus for processing photosensitive material.
NO913575L (no) Krokanordning for linefiske.
EP0585546A3 (de) Fotografisches Aufzeichnungsmaterial.
FR2657971B1 (fr) Diffuseur pour photomacrographie.
EP0608947A3 (en) Photographic processor.
FI904321A0 (fi) Anordning foer omplacering och aoterplacering av en videosignal.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 475623

Country of ref document: ES